Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
Public ClinicalTrials.gov record NCT04999020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis
Study identification
- NCT ID
- NCT04999020
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Interventions
- Ravulizumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2021
- Primary completion
- Oct 25, 2023
- Completion
- May 7, 2024
- Last update posted
- Jul 8, 2025
2021 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85032 | — |
| Research Site | Irvine | California | 92617 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Washington D.C. | District of Columbia | 20037 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Fairway | Kansas | 66205 | — |
| Research Site | Baltimore | Maryland | 21205 | — |
| Research Site | Las Vegas | Nevada | 89145 | — |
| Research Site | Manhasset | New York | 11030 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Memphis | Tennessee | 38120 | — |
| Research Site | North Richland Hills | Texas | 76180 | — |
| Research Site | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04999020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04999020 live on ClinicalTrials.gov.